Impact of homogeneous pathologic response to preoperative chemotherapy in patients with multiple colorectal liver metastases

Table 3 Univariate and multivariate analyses of factors associated with a homogeneous pathologic response to preoperative chemotherapy

Variable	Homogeneity (Rubbia-Brandt)				Homogeneity (MD - Anderson)
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	OR [95%CI]	P value	OR [95%CI]	P value	OR [95%CI]	P value	OR [95%CI]	P value
Age	2.33 [0.89-6.07]	0.82	/	/	1.5 [0.61-3.67]	0.37	/	/
Gender	1 [0.48-2.09]	0.99	/	/	1 [0.48-2.09]	0.99	/	/
Hypertension	1.13 [0.43-2.92]	0.81	/	/	1.13 [0.43-2.92]	0.81	/	/
Body mass index	0.99 [0.98-1.02]	0.95	/	/	1.01 [0.98-1.03]	0.86	/	/
Rectal cancer	1.14 [0.56-2.34]	0.72	/	/	1.73 [0.82-3.63]	0.15	/	/
Number of peroperative LM	0.96 [0.86-1.07]	0.45	/	/	0.99 [0.89-1.10]	0.87	/	/
Time interval between chemotherapy and surgery	3 [0.31-28.84]	0.34	/	/	1.5 [0.53-4.21]	0.44	/	/
Folfiri-based chemotherapy	0.007 [0.09-0.6]	0.90			0.8 [0.3-2.0]	0.60
Metachronous liver metastases	2.11 [0.96-4.67]	0.14	2.8 [0.92-8.5]	0.06	1.33 [0.63-2.82]	0.45	/	/
T stage	1.26 [0.73-2.18]	0.41	/	/	1.17 [0.68-2.01]	0.58	/	/
N0 stage	0.8 [0.22-2.98]	0.74	/	/	0.8 [0.22-2.98]	0.74	/	/
ASA score	1.05 [0.88-1.25]	0.62	/	/	1.05 [0.88-1.26]	0.56	/	/
MSI	1.9 [0.2-18.3]	0.90			1.5 [0.2-9.8]	0.60
RAS status	1.05 [0.0-99]	0.90			4.5 [0.8-23.9]	0.30
Braf mutation	1.6 [0.0-120]	0.90			3.3 [0.32-34.6]	0.30
Use of bevacizumab	3.20 [1.17-8.74]	0.02	3.5 [1.2-10.5]	0.02	1.33 [0.56-3.16]	0.51	/	/
Metastases in the left lobe of the liver	0.67 [0.24-1.87]	0.44	/	/	0.67 [0.24-1.87]	0.44	/	/
Number chemotherapy cycles	1.79 [0.93- 3.44]	0.12	1.06 [0.97-1.1]	0.10	1.44 [0.76- 2.72]	0.27	/	/

LM: Liver metastases.